文献速递湿疹皮炎与荨麻疹

特应性皮炎系统治疗缓解后持续应答:撤药、减量及延长间隔与继续治疗的网状Meta分析

Assessment of the Sustained Response to Systemic Treatment for Atopic Dermatitis in Patients Who Achieved Disease Remission: A Systematic Review and Network Meta-Analysis Comparing Withdrawal, Dose Reduction and Dosing Interval Extension Versus Continuation Therapy.
PubMed 文献 · Br J Dermatol · 2026-10-03

该系统综述与网状Meta分析比较特应性皮炎患者达缓解后撤药、减量或延长给药间隔与继续系统治疗对维持EASI75应答的效果。纳入55项研究89篇报告,网状Meta分析含9项研究2585例观察、13种方案。口服药撤药后早期复发风险高,生物制剂即使长期撤药或延长间隔仍可维持缓解,lebrikizumab表现更优。

要点

  • 口服系统治疗撤药后AD活动早期复发风险高。
  • 生物制剂长期撤药或延长给药间隔仍可维持EASI75应答。
  • lebrikizumab撤药或延长间隔的EASI75应答丢失风险低于其他方案。

核心结论

  • 口服系统治疗撤药后存在早期复发风险,而生物制剂即使长期撤药或延长给药间隔仍可维持缓解。
  • 特定情况下(如疫苗接种和妊娠)建议撤药,但需权衡口服治疗撤药后的复发风险。

研究设计与样本

  • 系统综述与网状Meta分析,检索PubMed、Embase、Web of Science和Scopus数据库。
  • 初检得21169篇文献,最终纳入55项研究的89篇报告。
  • 网状Meta分析基于9项研究、26对两两比较、13种方案、2585例观察。
  • 偏倚风险采用RoB-2和ROBINS-I工具评估,证据确定性采用GRADE框架。

主要发现

  • 原始数据分析显示多数活性治疗维持EASI75的风险比相当,但口服治疗撤药导致AD活动早期复发。
  • 网状Meta分析显示lebrikizumab撤药和延长给药间隔的EASI75应答丢失风险低于其他活性治疗的撤药、减量或延长间隔。
  • 亚组分析显示,在lebrikizumab诱导治疗后,安慰剂撤药或延长给药间隔维持EASI75应答的效果最佳。

关键数值与推荐

  • 主要结局为持续临床改善,以EASI75评估,评估时间为撤药、减量或延长给药间隔后16至52周。
  • 效应量以风险比(RR)比较。

临床怎么用

  • 对口服系统治疗获缓解的AD患者,撤药或减量需警惕早期复发。
  • 生物制剂治疗获缓解者可考虑延长给药间隔或短期撤药以维持缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent therapeutic advances transformed the management of atopic dermatitis (AD). Medication withdrawal, dose reduction and dosing interval extension are sometimes necessary when managing AD. OBJECTIVES: This review aims to compare the effectiveness of withdrawal, dose reduction and dosing interval extension with that of continuation of systemic therapy in sustaining remission among patients with AD. METHODS: A comprehensive search was conducted using the PubMed, Embase, Web of Science, and Scopus databases. Study selection was performed independently by two reviewers, and discrepancies were resolved by a third reviewer. The risk of bias was evaluated using the Cochrane risk of bias tool for randomized trials (RoB-2) and the Risk of Bias in Nonrandomized Studies of Interventions (ROBINS-I) tool. The certainty of the evidence was determined in accordance with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. The primary outcome was defined as sustained clinical improvement, measured by a 75% reduction in the Eczema Area and Severity Index (EASI), which was assessed 16 to 52 weeks after treatment withdrawal, dose reduction or dosing interval extension. Risk ratios (RRs) were compared using a network meta-analysis (NMA). RESULTS: After the initial search yielded 21,169 references, 89 reports representing 55 studies were included. Raw data analysis indicated that most active treatments showed comparable RRs for EASI75 maintenance, whereas the discontinuation of oral therapies led to early relapses in AD activity. On the basis of 9 studies encompassing 26 pairwise comparisons and 2,585 observations across 13 regimens, our NMA revealed that lebrikizumab withdrawal and dosing interval extension conferred a lower risk of EASI75 response loss than withdrawal, dose reduction, or dosing interval extension with other active therapies did. A subgroup analysis also revealed that the maintenance of EASI75 responses after placebo withdrawal or dosing interval extension was greatest for induction dosing with lebrikizumab. CONCLUSIONS: While the withdrawal of systemic therapy is recommended in certain circumstances, such as during vaccination and pregnancy, the evidence reveals an early risk of relapse following the withdrawal of oral treatments. In contrast, biologic therapies resulted in sustained remission rates, even after prolonged withdrawal or dosing interval extension periods.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Nakano J, Barroso LF, de Carvalho Mesquita K, et al. Assessment of the Sustained Response to Systemic Treatment for Atopic Dermatitis in Patients Who Achieved Disease Remission: A Systematic Review and Network Meta-Analysis Comparing Withdrawal, Dose Reduction and Dosing Interval Extension Versus Continuation Therapy. Br J Dermatol. 2026. PMID: 42827390. doi:10.1093/bjd/ljag436

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。